Bilateral Superior Branch Retinal Artery Occlusions in a Patient on Pembrolizumab.

Abstract

To describe a case of bilateral, multiple branch retinal artery occlusions (BRAO) in a woman on pembrolizumab immunotherapy for metastatic uterine cancer.Case report of one patient and literature review.A female in her mid-40s with obesity, hypertension, type 2 diabetes, and metastatic uterine cancer status post chemotherapy, debulking surgery, and whole-brain radiation presented with bilateral worsening of vision and a symptomatic scotoma in her right eye. Ten months prior to presentation, she was found to have recurrence of her cancer and was started on immunotherapy with pembrolizumab and lenvatinib. Dilated fundus examination showed vascular tortuosity, intraretinal hemorrhages, microaneurysms, and macular edema in both eyes. The macular edema was attributed to diabetic retinopathy and was treated with intravitreal bevacizumab. Although there was improvement of edema on optical coherence tomography, her vision did not significantly improve. Over sixteen months, her vision worsened from 20/40 and 20/50 to 20/200 and 20/150 in the right and left eye, respectively. Fluorescein angiography was performed and revealed multiple, bilateral branch retinal artery occlusions, symmetrically involving the superior arterial vessels in both eyes. Extensive imaging and laboratory work-up was negative. Her BRAOs were attributed to pembrolizumab.Pembrolizumab can be associated with multiple branch retinal artery occlusions. Fluorescein angiography is a useful tool in distinguishing between etiologies of retinal vascular disease. Oncologic and ophthalmologic providers should be cognizant of this rare cause of vision loss and screen appropriately.

View details for DOI 10.2147/IMCRJ.S584574

View details for PubMedID 41907569

View details for PubMedCentralID PMC13031259